LEO Pharma Reports the US FDA’s sNDA Acceptance of Anzupgo for Use in Children with Chronic Hand Eczema

Why It Matters

Anzupgo offers the first JAK‑inhibitor‑based topical option for pediatric chronic hand eczema, addressing a sizable unmet need and opening a new revenue stream for LEO Pharma. Its acceptance signals broader regulatory openness to pediatric dermatology indications.

Key Takeaways

• FDA accepted sNDA for Anzupgo in 12‑17‑year‑olds
• DELTA TEEN trial met primary IGA‑CHE improvement at week 16
• Study showed significant secondary endpoint benefits over vehicle cream
• EU regulatory review now underway, expanding global reach

Pulse Analysis

Chronic hand eczema (CHE) in children is more than a cosmetic concern; it can impair daily activities, cause sleep disruption, and increase the risk of infection. Traditional management relies on high‑potency topical corticosteroids, which carry risks of skin atrophy and are often unsuitable for long‑term use in younger patients. Consequently, clinicians have long sought safer, targeted therapies that can control inflammation without the side‑effects associated with steroids.

Anzupgo (delgocitinib) is a topical Janus kinase (JAK) inhibitor that blocks the JAK‑STAT pathway, a key driver of inflammatory skin disorders. In the DELTA TEEN Phase III trial, adolescents receiving 20 mg/g twice daily achieved a marked reduction in Investigator’s Global Assessment scores by week 16, surpassing the vehicle group. The trial also met its secondary efficacy endpoints, including itch reduction and quality‑of‑life improvements, underscoring the cream’s potential to become a first‑line option for pediatric CHE where steroids fall short.

The FDA’s acceptance of the supplemental NDA positions LEO Pharma to capture a niche yet growing market segment. With the European Union now reviewing the application, the company could soon secure a dual‑market launch, leveraging its existing dermatology portfolio. The move also reflects a broader industry trend toward expanding JAK‑inhibitor indications into pediatric dermatology, suggesting that future pipelines may increasingly target younger demographics with precision‑focused, steroid‑sparing treatments. This regulatory momentum could accelerate adoption, drive revenue diversification, and reinforce LEO Pharma’s standing as an innovator in skin‑health therapeutics.